BioSpace News Archive

REGENXBIO Inc. announced the closing of its previously announced underwritten public offering of 2,700,000 shares of its common stock at a price to the public of $65.00 per share

Management to Host Conference Call and Webcast Today, August 14, 2018 at 4:30 p.m. Eastern (1:30 p.m. Pacific)

Sophiris Bio Inc. reported financial results for the second quarter 2018 and recent corporate highlights.

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on October 8, 2018 to all shareholders of record as of September 14, 2018.

Innovus Pharmaceuticals, Inc. today reported results for the second quarter 2018.

SeniorWell, a mobile healthcare company delivering podiatry, optometry, dentistry, and audiology services to a variety of senior-assistance communities across the Midwest, today announced its partnership with Dr. Lowell Weil, Jr. of Weil Foot & Ankle Institute.

U. S. News & World Report released its 2018-2019 Best Hospitals National Ranking and the Department of Orthopaedic Surgery at Rush University Medical Center (RUMC), consisting of Midwest Orthopaedics at Rush (MOR) physicians, moved from the fifth to the fourth best orthopedic program in the nation.

ContraFect Corporation announced that Cara Cassino, M.D., the Company’s Executive Vice President of Research and Development and Chief Medical Officer, has been invited by the Food and Drug Administration (FDA) to participate in a panel discussion for a public workshop entitled “Development of Non-Traditional Therapies for Bacterial Infections”.

Organovo Holdings, Inc. announced the grant of inducement awards on August 14, 2018 to Dr. Steven G. Hughes, its new chief medical officer.

Taiwan Liposome Company, Ltd. (4152.TWO; “TLC”), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of medical needs in pain management, ophthalmology, and oncology, today announced the dosing of the first patients in a Phase I/II trial for TLC590.